22 May 2012 15:46
22 May 2012
Instem plc
(the "Company")
Result of AGM
Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce that all resolutions were duly passed at the Company's Annual General Meeting held earlier today.
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Brewin (Nominated Adviser & Broker) | +44 (0) 20 3201 3710 |
Aubrey Powell | |
Luke Boyce | |
Newgate Threadneedle | +44 (0) 20 7653 9850 |
Caroline Evans-Jones | |
Fiona Conroy | |
About Instem plc
Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.
In March 2011 Instem acquired BioWisdom Limited, subsequently renamed Instem Scientific Limited ("Instem Scientific"), a leading provider of software solutions for extracting intelligence from R&D related healthcare data. The acquisition broadened and strengthened Instem's Centrus™ product suite, accelerating the product development roadmap.
Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in six offices in the US, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.
To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.